Why Did NLS Pharmaceutics Soar 13.79%?

On July 1, 2025, NLS Pharmaceutics surged 13.79% in pre-market trading, marking a significant rise in its stock price.

NLS Pharmaceutics and Kadimastem recently announced the closing of a $1 million equity financing round, following an initial $2 million round on March 28, 2025. This brings the total gross proceeds from the equity financing to $3 million. The successful completion of this financing round is expected to bolster the company's financial position and support its ongoing research and development efforts.

In January 2021, NLS Pharmaceutics raised $20 million through an initial public offering (IPO), issuing 3.6 million shares at a price range of $5.00 to $6.00 per share. This IPO provided the company with substantial capital to advance its pharmaceutical initiatives and expand its market presence.